Investigating the effects of serotonin receptor modulation on brain function
Official title: The Neurobiological Effect of 5-HT2AR Modulation
Run by Copenhagen University Hospital, Rigshospitalet · NCT03289949 · Data updated 2026-11-12
This study tests how two different substances, psilocybin and ketanserin, affect brain function and mood in healthy volunteers to better understand their impact on the brain.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Copenhagen University Hospital, Rigshospitalet Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Copenhagen) |
| Status | Recruiting |
| Started | March 3, 2017 |
| Main results expected | June 1, 2030 |
| Study ends | June 1, 2030 |
| Registry record updated | December 16, 2024 |
| Trial ID | NCT03289949 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy individuals over the age of 18 without a history of psychiatric or neurological disorders.
✕Probably not a fit
Patients with a history of psychiatric diseases, neurological conditions, or those who are pregnant or breastfeeding may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project explores the neurobiological effects of serotonin 2A receptor modulation in healthy volunteers by comparing the effects of psilocybin, a 5-HT2AR agonist, and ketanserin, a 5-HT2AR antagonist. Using advanced neuroimaging techniques such as MRI and PET, the study aims to elucidate how these substances influence brain function and mood. The goal is to identify the neural mechanisms underlying the clinical effects of psilocybin and establish a framework for understanding pharmacological impacts on the human brain.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of mood regulation and the therapeutic potential of psychedelics in treating mental health conditions.
How similar studies have gone: Other studies have shown promising results in understanding the effects of psychedelics on brain function, suggesting that this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1\) Healthy individuals above 18 years of age. Exclusion Criteria (For Subprojects 1, 2a, 2b, and 3): 1. Presence of or previous primary psychiatric disease (DSM axis 1 or WHO ICD-10 diagnostic classifications) or in first-degree relatives. 2. Previous or present neurological condition/disease, significant somatic condition/disease or intake of drugs suspected to influence test results. 3. Non-fluent Danish language skills. 4. Vision or hearing impairment. 5. Previous or present learning disability. 6. Pregnancy. 7. Breastfeeding. 8. Contraindications in regard to MRI scanning. 9. Alcohol or drug abuse. 10. Allergy to test drugs. 11. Participation in studies in which participant has received more than 10 mSv of radiation or other significant exposure to radiation. 12. Abnormal ECG or intake of QT prolonging medication. 13. Previous significant side-effects in regard to hallucinogenic drugs. 14. Use of hallucinogenic drugs 6 months previous to inclusion. 15. Blood donation 3 months before and after project participation 16. Body weight under 50 kg. 17. Plasma ferritin levels outside normal range Exclusion Criteria (For Subproject 2c): 1. Presence of or previous primary psychiatric disease (DSM IV axis 1 or WHO ICD-10 diagnostic classifications). 2. Presence of or previous primary psychiatric disease with psychosis symptoms or hypomania (DSM IV axis 1 \[drug/alcohol abuse/dependence, schizophrenia and other psychoses\] or WHO ICD-10 diagnostic classifications \[F10-29, as well as F30-39 with psychotic symptoms, F60\]) in first-degree relatives (parents or siblings). 3. Previous or present neurological condition/disease, significant somatic condition/disease or intake of drugs suspected to influence test results. 4. Non-fluent Danish language skills or pronounced vision or hearing impairment. 5. Previous or present learning disability. 6. Pregnancy. 7. Breastfeeding. 8. Contraindications in regard to MRI scanning. 9. Alcohol or drug abuse. 10. Allergy to test drugs. 11. Abnormal ECG or intake of QT prolonging medication. 12. Previous significant side-effects in regard to hallucinogenic drugs. 13. Previous use of hallucinogenic drugs. 14. Body weight under 45 kg. 15. Ethical concerns regarding the administration of a psychedelic drug.
Where it's running
-
Neurobiology Research Unit, Rigshospitalet
Copenhagen, Denmark Recruiting
Study contacts
- Study coordinator: Gitte M Knudsen, Professor
- Email: gmk@nru.dk
- Phone: +45 35456720
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding how the brain learns to control hand movements
This study is testing how the brain learns to control hand movements in different situations to help improve rehabilitation for people with brain injuries.
-
Oral switch for bloodstream infections in immunocompromised children
This trial tests whether switching from IV to oral antibiotics is just as safe as continuing IV therapy for children with bloodstream infections who are immunocompromised or have a central venous catheter.
-
Proton Therapy for Mediastinal Lymphoma in Denmark
This study tests whether using proton therapy for mediastinal lymphoma can lower late-toxicity risk compared with photon therapy in adults.
-
Oral switch for kids with bloodstream infections after starting IV therapy
This trial will test whether switching from IV to oral antibiotics early is not worse than continuing IV treatment for previously healthy children and teens with uncomplicated bloodstream infections.
-
Unilateral vs bilateral lung volume reduction surgery for emphysema
This trial tests whether operating on one lung or both lungs provides better breathing and quality of life for adults with severe emphysema due to COPD.
-
Scar remodeling after burn injury using stem cells from fat tissue
This trial tests whether injecting allogeneic adipose-derived stem cells into burn scars can improve scar quality for adults with hypertrophic scars.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.